Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

The Effect of Neurontin on Pain Management in the Acutely Burned Patient

This study has been completed.
Information provided by (Responsible Party):
Wibbenmeyer, Lucy A, University of Iowa Identifier:
First received: December 20, 2010
Last updated: November 30, 2015
Last verified: January 2013
Burn patients have extreme pain. Opioids are the main agents used for analgesia. Opioids can have several adverse outcomes and have been only partially effective in controlling the pain assoicated with burn injury. Agents directed at neuropathic pain are rarely used acutely in thermal injury. However, there is mounting evidence from small randomized clinical studies that the administration of the anticonvulsant Gabapentin decreases acute burn pain and has an opioid sparing effect. We therefore propose a single center study to fruther assess the efficacy of neuropathic agents in controlling the pain associated with acute thermal injury.

Condition Intervention
Burn Injury
Drug: Gabapentin
Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: The Effect of Neurontin on Pain Management in the Acutely Burned Patient

Resource links provided by NLM:

Further study details as provided by University of Iowa:

Primary Outcome Measures:
  • To Determine the Trends in Opioid Consumption Between the Treatment and the Control Groups. [ Time Frame: From time of enrollment to 2 weeks after being discharged ]

Secondary Outcome Measures:
  • To Determine the Trends in Several Associated Clinical Effects of Opioid Administration Between the Treatment and the Control Groups. These Effects Include: 1. Fluid Resusitation 2. Insulin Resistance 3. Hospital Associated Infections [ Time Frame: From time of enrollment to 2 weeks after being discharge ]
  • To Determine the Impact of Psychological Functioning in Patients Following Admission for Their Burn Injury. This Will be Determined by Review of Two Forms (the Brief Symptom Inventory and the Sickness Impact Profile). [ Time Frame: From time of enrollment to 2 weeks after being discharge ]

Enrollment: 53
Study Start Date: February 2010
Study Completion Date: September 2011
Primary Completion Date: September 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Sugar Pill
Drug: Placebo
Sugar Pill is administered similar to the protocol used for the investigational drug.
Experimental: Gabapentin
Drug: Gabapentin

On Study day 1: 1200mg (single dose).

Study day 2,3: 300mg TID, 900mg daily.

Study day 4-7: 600mg TID 1800mg* daily.

Study day 8-11: 800mg TID 2400mg* daily [Optional increase to 2400 if pain scores are still 4 on NRS]

Study day 11: 1200mg TID 3600mg* daily [Optional increase to 3600 if pain scores are still >4 on NRS]

* May revert back to prior dose if adverse symptoms occur and are thought to be drug related. Up titration then will be preformed in 48 hours following deexcalation.

Other Name: Neurontin

Detailed Description:
see above

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All admitted patients with LOS expected to be > 48 hours (usually burn injury > 5%)
  • > 18 years of age
  • Thermal injury to skin

Exclusion Criteria:

  • Prisoners
  • Pregnant or nursing women
  • Children <18 years of age
  • Frostbite or non thermal injury to skin
  • Renal insuffiency (creatinine clearance < 60mL/min) or failure (on renal replacement)
  • Expected length of stay < 48 hours (this usually includes burn <5%
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01265056

United States, Iowa
University of Iowa Burn Center
Iowa City, Iowa, United States, 52241
Sponsors and Collaborators
University of Iowa
Principal Investigator: Lucy Wibbenmeyer, MD University of Iowa
  More Information

Responsible Party: Wibbenmeyer, Lucy A, Associate Clinical Professor, University of Iowa Identifier: NCT01265056     History of Changes
Other Study ID Numbers: 200909736
Study First Received: December 20, 2010
Results First Received: January 22, 2013
Last Updated: November 30, 2015

Additional relevant MeSH terms:
Wounds and Injuries
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Antimanic Agents processed this record on May 22, 2017